未登录.png)
分享.png)
收藏分享 收藏 分享 收藏 分享 收藏 分享 收藏 分享 收藏 Atezolizumab and Trastuzumab Plus Chemotherapy for ERBB2-Positive Locally Advanced Resectable Gastric Cancer: A Randomized Clinical Trial阿特珠单抗和曲妥珠单抗联合化疗用于ERBB2阳性局部晚期可切除胃癌：一项随机临床试验
Peng, Zhi; Zhang, Xiaotian; Liang, Han; Zheng, Zhichao; Wang, Zhenning; Liu, Hao; Hu, Jiankun; Sun, Yihong; Zhang, Yanqiao; Yan, Han; Tong, Lin; Xu, Jiahui; Ji, Jiafu; Shen, Lin 分享 收藏 分享 收藏 First-Line Sugemalimab Plus Chemotherapy for Advanced Gastric Cancer: The GEMSTONE-303 Randomized Clinical TrialFirst-Line Sugemalimab Plus Chemotherapy for Advanced Gastric Cancer: The GEMSTONE-303 Randomized Clinical Trial
一線蘇吉帕利单抗联合化疗用于晚期胃癌：GEMSTONE-303隨機臨床試驗Zhang, Xiaotian; Wang, Jufeng; Wang, Gang; Zhang, Yanqiao; Fan, Qingxia; Lu, Chuangxin; Hu, Changlu; Sun, Meili; Wan, Yiye; Sun, Sanyuan; Wang, Junye; Zhang, Li; Shu, Yongqian; Luo, Jie; Zhu, Dan; Shen, Zhenwei; Yao, Sheng; Shi, Qingmei; Yang, Jason 分享 收藏 The anti-PD-L1/CTLA-4 bispecific antibody KN046 plus lenvatinib in advanced unresectable or metastatic hepatocellular carcinoma: a phase II trial抗PD-L1/CTLA-4双特异性抗体KN046联合仑伐替尼在晚期不可切除或转移性肝细胞癌中的治疗：一项II期临床试验Xu, Da; Wang, Hongwei; Bao, Quan; Jin, Kemin; Liu, Ming; Liu, Wei; Yan, Xiaoluan; Wang, Lijun; Zhang, Yanqiao; Wang, Guangyu; Ma, Yue; Ma, Zhigang; Zhang, Chunhui; Tang, Jiebing; Wang, Sha; Pang, Jiaohui; Xu, Ting; Wang, Kun; Xing, Baocai 分享 收藏 Tumor aggression-defense index-a novel indicator to predicts recurrence and survival in stage II-III colorectal cancer肿瘤攻击防御指数-预测 ⅱ-ⅲ 期结直肠癌复发和生存的新指标Wu, Tong; Fang, Lin; Ruan, Yuli; Shi, Mengde; Su, Dan; Ma, Yue; Ma, Ming; Wang, Bojun; Liao, Yuanyu; Han, Shuling; Lu, Xiaolin; Zhang, Chunhui; Liu, Chao; Zhang, Yanqiao 分享 收藏 Mevalonate kinase inhibits anti-tumor immunity by impairing the tumor cell-intrinsic interferon response in microsatellite instability colorectal cancerLiao, Yuanyu; Yang, Rui; Wang, Bojun; Ruan, Yuli; Cui, Luying; Yang, Jiani; Yu, Xuefan; Han, Shuling; Yao, Yuanfei; Luan, Xindi; Li, Yingjue; Shi, Mengde; Li, Shuijie; Liu, Chao; Zhang, Yanqiao 分享 收藏 A randomized phase 2 study of HLX22 plus trastuzumab biosimilar HLX02 and XELOX as first-line therapy for HER2-positive advanced gastric cancerLi, Ning; Qiu, Meng; Zhang, Yanqiao; Yang, Mudan; Lu, Linzhi; Li, Wei; Ma, Yuntao; Hou, Xiaoming; Sun, Guoping; Cai, Mingquan; Wang, Jingran; Lu, Jianwei; Zhong, Diansheng; Huo, Zhibin; Zhang, Jingdong; Yin, Xianli; Deng, Jun; Liu, Zimin; Pan, Hongming; Chen, Ye; Yang, Futang; Yu, Haoyu; Li, Jing; Wang, Qingyu; Zhu, Jun; Li, Jin 分享 收藏 分享 收藏 Irinotecan plus raltitrexed as second-line treatment in locally advanced or metastatic colorectal cancer patients: a prospective open-label, single-arm, multi-center, phase II studyCheng, Yu; Teng, Zan; Zhang, Yanqiao; Jin, Bo; Zheng, Zhendong; Man, Li; Wang, Zhenghua; Teng, Yuee; Yu, Ping; Shi, Jing; Luo, Ying; Wang, Ying; Zhang, Jingdong; Zhang, Huijuan; Liu, Jiwei; Chen, Hao; Xiao, Jiawen; Zhao, Lei; Zhang, Lingyun; Jiang, Yu; Chen, Ying; Zhang, Jian; Wang, Chang; Liu, Sa; Qu, Jinglei; Qu, Xiujuan; Liu, Yunpeng 分享 收藏 SALIRI-based (raltitrexed plus irinotecan) therapy as a second-line treatment for patients with metastatic colorectal cancer (SALLY): A prospective, multicenter, non-interventional, registry study基于SALIRI的 (雷替曲塞联合伊立替康) 疗法作为转移性结直肠癌患者的二线治疗 (SALLY): 一项前瞻性，多中心，非干预性，注册研究Qin, Shuqui; Li, Jin; Zhou, Aiping; Zhang, Yanqiao; Yuan, Xianglin; Zhu, Liangjun; Qin, Baoli; Zeng, Shan; Shen, Lin; Yuan, Ying; Wang, Weibo; Liang, Jun; Zhang, Xianwen; Ye, Feng; Chen, Ping; Wang, Huaizhang; Yu, Zhenyan; Yue, Lu; Fang, Yong; Xiong, Jianping; Yang, Jianwei; Wan, Yiye; Yin, Xianli; Wang, Wenling; Xu, Nong; Wang, Xiaohong; Xiao, Zemin; Su, Huafang; Wang, Ying; Gu, Kangsheng; Tu, Shuiping; Wang, Zishu; Liu, Bo; Hu, Xiaohua; Liu, Weixian; Li, Xiaofeng 分享 收藏 Effects of sintilimab plus chemotherapy as fi rst-line treatment on health-related quality of life in patients with advanced esophageal squamous cell carcinoma: results from the randomized phase 3 ORIENT-15 studyLu, Zhihao; Kong, Li; Wang, Buhai; Wang, Junye; Liu, Lianke; Shu, Yongqian; Yang, Lei; Sun, Guogui; Cao, Guochun; Ji, Yinghua; Cui, Tongjian; Liu, Hu; Qiu, Wensheng; Li, Na; Li, Gaofeng; Luo, Hui; Hou, Xinfang; Zhang, Yanqiao; Yue, Wenbin; Xue, Liying; Liu, Zheng; Pan, Yueyin; Gao, Shegan; Wang, Xiuwen; Pan, Zhanyu; Zhang, Shuqun; Lin, Gen; Xie, Yanru; Gu, Kangsheng; Ren, Tiejun; Li, Weidong; Li, Tao; Wang, Shoufeng; He, Wei; Fan, Yun; Liang, Jun; Xia, Bing; Zhao, Li; Wang, Shuxuan; Shen, Lin 分享 收藏 Inhibition of HDAC2 sensitises antitumour therapy by promoting NLRP3/GSDMD-mediated pyroptosis in colorectal cancer通过促进NLRP3/GSDMD介导的结直肠癌焦亡抑制HDAC2增敏抗肿瘤治疗Guan, Xin; Liu, Ruiqi; Wang, Bojun; Xiong, Ruxin; Cui, Luying; Liao, Yuanyu; Ruan, Yuli; Fang, Lin; Lu, Xiaolin; Yu, Xuefan; Su, Dan; Ma, Yue; Dang, Tianjiao; Chen, Zhuo; Yao, Yuanfei; Liu, Chao; Zhang, Yanqiao 分享 收藏 Dynamic radiological features predict pathological response after neoadjuvant immunochemotherapy in esophageal squamous cell carcinoma动态放射学特征预测食管鳞癌新辅助免疫化疗后的病理反应Ruan, Yuli; Ma, Yue; Ma, Ming; Liu, Chao; Su, Dan; Guan, Xin; Yang, Rui; Wang, Hong; Li, Tianqin; Zhou, Yang; Ma, Jianqun; Zhang, Yanqiao 分享 收藏 Efficacy and safety of tislelizumab plus lenvatinib as first-line treatment in patients with unresectable hepatocellular carcinoma: a multicenter, single-arm, phase 2 trialtislelizumab联合lenvatinib作为一线治疗不可切除肝细胞癌患者的疗效和安全性: 一项多中心，单臂，2期试验Xu, Li; Chen, Jinzhang; Liu, Chang; Song, Xiaoling; Zhang, Yanqiao; Zhao, Haitao; Yan, Sheng; Jia, Weidong; Wu, Zheng; Guo, Yabing; Yang, Jiayin; Gong, Wei; Ma, Yue; Yang, Xiaobo; Gao, Zhenzhen; Zhang, Nu; Zheng, Xin; Li, Mengyu; Su, Dan; Chen, Minshan 分享 收藏 
.png){kind=icon}
.png){kind=icon}
.png)
CANCER COMMUNICATIONS.png)
OAAI